Nexplanon Lawsuit: Claims, Status, and Payouts

A Nexplanon lawsuit is a personal injury claim against Organon, the manufacturer of the etonogestrel birth control implant, alleging that the device caused serious harm and that the company failed to warn patients and doctors about known risks. Hundreds of women have sued over injuries including implant migration into the chest or lungs, nerve damage, blood clots, and a dangerous buildup of pressure inside the skull. As of mid-2026, these are individual cases rather than a certified class action, and no global settlement has been reached.¹

What Plaintiffs Are Claiming

Most Nexplanon suits press two product-liability theories: that the device is defectively designed, and that Organon (and previously Merck) knew about serious complications but failed to update warnings as adverse-event reports accumulated.²

The injuries alleged fall into several categories:

Device migration. The implant can travel from the upper arm into the chest wall, blood vessels, or the pulmonary artery. A study of FDA adverse-event reports identified 38 unique cases of pronounced migration through November 2015, with nine involving the lung or pulmonary artery and 14 involving other blood vessels. Retrieval sometimes requires open-heart or thoracic surgery, and in some cases the device cannot be safely removed at all.³²
Nerve damage. Patients report pain, numbness, and tingling from ulnar or median nerve irritation. Medical literature identifies deep insertion, intramuscular placement, and localized inflammatory swelling as mechanisms that can compress nearby nerves.⁴
Blood clots. Suits cite deep vein thrombosis, pulmonary embolism, heart attack, and stroke. The FDA added warnings for these conditions to the Nexplanon label in 2023.⁵
Pseudotumor cerebri, also called benign intracranial hypertension. Plaintiffs allege that etonogestrel can trigger this pressure buildup around the brain, causing severe headaches, vision problems, and in some cases permanent blindness.²
Unintended pregnancy. Some claims allege the implant failed or was never properly inserted. This was more common in earlier litigation over Nexplanon’s predecessor, Implanon.⁶

Where the Litigation Stands

There is no certified class action against Organon or Merck over Nexplanon. Each plaintiff’s claim is evaluated on her own medical evidence.¹

Public case counts vary. One source reports 18 pending lawsuits involving Nexplanon and its predecessor Implanon as of June 2026, with over 50 additional unfiled Implanon cases.⁵ Another reports more than 1,500 cases being evaluated in an MDL process as of early 2025.⁷ A third describes the litigation as organized within a federal multidistrict litigation framework, with active discovery and movement toward bellwether trials.² The differences likely reflect different stages of evaluation and different definitions of “pending.”

Merck’s SEC filings as of mid-2025 disclosed just one Nexplanon product-liability case pending in a California state court and 10 cases pending outside the United States.⁸ That low number reflects the indemnification arrangement described below: Organon, not Merck, now bears the exposure.

Settlements and Potential Payouts

The most widely reported resolution is a 2021 medical malpractice settlement in South Carolina, not a manufacturer settlement. A Beaufort County woman alleged that staff at the Beaufort Clinic improperly placed her Nexplanon implant in January 2014, leading to multiple follow-up visits for removal and permanent nerve damage in her arm. The South Carolina Insurance Reserve Fund paid $600,000 to resolve the suit. The defendant was the clinic, owned by the state with Beaufort County, so this was a claim against a provider for improper insertion rather than a product-liability claim against Organon.⁹¹⁰

No large-scale settlements in the product-liability litigation against the manufacturer have been publicly announced. Projected individual payouts vary widely with injury severity. One analysis estimates a range from $50,000 for less severe cases to over $1,000,000 for cases involving neurological conditions like pseudotumor cerebri.²

Manufacturer Claim or Malpractice Claim?

Which kind of lawsuit fits a given injury matters enormously. If the implant caused harm because of its design or because the manufacturer concealed a known risk, that is a product-liability case against Organon. If the harm came from a clinician inserting the device too deeply or failing to verify its position, that is a medical malpractice case against the provider. Both can apply at once. A design that permits easy migration combined with an improperly deep insertion can produce a pulmonary artery complication that supports claims against both defendants.⁷

Organon maintains that Nexplanon is safe and effective when used as directed and that its labeling appropriately discloses known risks.²

Why the FDA Label Changes Matter

Failure-to-warn claims often hinge on what the manufacturer knew about a risk and when it told doctors and patients, so regulatory action tracks closely with the litigation. In 2023, the FDA updated the Nexplanon label to add warnings for pulmonary embolism, heart attack, deep vein thrombosis, and blood clotting.⁵ Earlier revisions in 2020 addressed complications from insertion and removal as well as broken or bent implants.¹¹

On January 16, 2026, the FDA approved a supplemental application that extended the approved duration of use from three years to five years and imposed a new Risk Evaluation and Mitigation Strategy (REMS).¹² Under the REMS, every clinician who inserts or removes Nexplanon must complete a certification program that includes online training, an in-person session from Organon, and a seven-question knowledge assessment. Pharmacies must also be certified, and wholesalers may supply the device only to certified providers and pharmacies. The enrollment deadline is August 23, 2026.¹³

The updated label now carries a boxed warning, the FDA’s most prominent safety alert, about complications from improper insertion and removal. It explicitly warns that migration into the pulmonary artery has been reported and describes symptoms including chest pain, difficulty breathing, cough, and coughing up blood.¹⁴

Who Actually Pays: Organon vs. Merck

Merck marketed Nexplanon for years after acquiring the original developer. In June 2021, Merck spun off its women’s health portfolio into a new public company, Organon & Co., and Nexplanon went with it.¹⁵

Under the Separation and Distribution Agreement, Organon must indemnify Merck for any liabilities arising from products transferred in the spinoff, including Nexplanon.⁸ So even when Merck is named as a defendant in older filings, Organon carries the financial exposure. Organon records accruals for product-liability contingencies when a loss is probable and reasonably estimable, and has disclosed that it carries no insurance for most product liabilities, having determined the cost outweighs the likely benefit of available coverage.¹⁵

What Makes These Cases Hard to Win

Courts require plaintiffs to produce specific medical evidence connecting the implant to their injury. General reports of complications are not enough to establish legal causation on their own.¹ Expert testimony from physicians, engineers, and product-design specialists is typically necessary, and those experts can charge $1,000 or more per hour for trial testimony.¹⁶ The FAERS data showing an increasing pattern of migration reports beginning in 2013, combined with the 2023 blood clot warnings and the 2026 boxed warning about improper insertion, give plaintiffs’ lawyers a documentary record to work from on the failure-to-warn side. Whether that record is enough to move individual cases toward larger settlements will depend on how discovery and any bellwether trials unfold.

1
Injury Report USA. Nexplanon Lawsuit
2
Lawfold. Nexplanon Lawsuit
3
ScienceDirect. Etonogestrel Implant Migration FAERS Study
4
National Library of Medicine. Nexplanon Neuropathy Case Report
5
Schmidt & Clark. Nexplanon Lawsuit
6
Toledo Law. Lost Implanon Implants
7
Personal Injury Law Cal. What Is the Average Nexplanon Settlement
8
SEC. Merck SEC Filing
9
Live 5 News. SC Woman Receives 6-Figure Payout in Birth Control Implant Lawsuit
10
Live Action. Woman Settlement Birth Control Implant
11
FDA. Nexplanon FDA Label
12
UCSF ReproHH. FDA Approves Updated Nexplanon Label and Launches New REMS
13
Reproductive Access. New FDA REMS Requirement on Nexplanon
14
FDA. Nexplanon Prescribing Information
15
Cloudfront. Organon Annual Report
16
Avvo. Can I Sue Nexplanon for Giving Me Pseudotumor Cerebri